ArticleAMB Express2025
Carbapenem resistance in enterotoxigenic Bacteroides fragilis isolated from colonoscopy candidates.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Significance ofMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to determine the carbapenem resistance among Enterotoxigenic Bacteroides fragilis (ETBF) isolated from patients candidates to colonoscopy in Shiraz, Iran. A total of 201 stool samples were gathered from 201 patients. The detection of B. fragilis group, B. fragilis, and ETBF was performed using a PCR assay targeting bfg, 16S rRNA, and bft genes, respectively. The enterotoxin isotype-encoding genes (bft-1, bft-2, and bft-3) were detected in ETBF using a PCR assay. Antimicrobial susceptibility profile of ETBF against imipenem and meropenem was determined using the Liofilchem® MIC Test Strips. The Ana-CIM assay was used for the phenotypic detection of carbapenemase production in ETBF strains. The presence of the cfiA and insertion sequence (IS) encoding genes (IS1186, IS1187, IS1188, IS942) was determined using a PCR assay. Overall, 71.64%, 33.83%, and 20.4% of patients were positive for B. fragilis group, B. fragilis, and ETBF, respectively. 28 (68.3%) tested positive for the bft-1 gene, whereas only one isolate (2.4%) contained the bft-3 gene. 80% (n = 4/5) of patients with polyp in sigmoid colon + colorectal polyp and 72.7% (n = 8/11) of patients with hemorrhoids were positive to ETBF. 2.4% and 48.8% of ETBF isolates were resistant to imipenem and meropenem, respectively. Out of the 41 ETBF isolates, 28 (68.3%) were positive for carbapenemase production. 46.3% (n = 18/41) of ETBF were positive for the cfiA gene. 27 isolates (96.4%) harbored the IS1187 gene. Resistance rates of ETBF to meropenem were high. Most patients with a polyp in the sigmoid colon, colorectal polyp, and hemorrhoids were positive for ETBF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.